Robert McKinney, MD
Internal Medicine · Corinth, MSNPI 1861485179
Payments from drug & device makers
Across 228 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$429
- AstraZeneca$398
- Daiichi Sankyo Inc.$313
- Amgen$298
- Bayer$268
- AbbVie$246
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $429 |
| AstraZeneca | 24 | $398 |
| Daiichi Sankyo Inc. | 18 | $313 |
| Amgen | 19 | $298 |
| Bayer | 15 | $268 |
| AbbVie | 25 | $246 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $168 |
| Pfizer | 11 | $159 |
| Lilly USA, LLC | 10 | $151 |
| Abbott | 7 | $139 |
| Amarin Pharma, Inc. | 7 | $138 |
| Astellas Pharma US Inc | 5 | $132 |
| Merck | 3 | $127 |
| Pharmacosmos Therapeutics Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $67 |
| Exact Sciences | 4 | $61 |
| Biohaven Pharmaceuticals, Inc. | 4 | $54 |
| Hologic Sales And Service, LLC | 1 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Mckesson Medical-surgical, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$3,634 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $42,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $42,671 |
| FarxigaDapagliflozin Propanediol | 49 | $34,554 |
| TrulicityDulaglutide | 20 | $25,295 |
| EliquisApixaban | 40 | $25,064 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $16,393 |
| RybelsusSemaglutide | 14 | $12,143 |
| MounjaroTirzepatide | 12 | $12,063 |
| Repatha SureclickEvolocumab | 21 | $11,416 |
| KerendiaFinerenone | 14 | $11,334 |
| QuliptaAtogepant | 11 | $11,010 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $9,911 |
| JanuviaSitagliptin Phosphate | 16 | $9,907 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,301 |
| VascepaIcosapent Ethyl | 13 | $6,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $429 | $54,91057 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $398 | $41,85561 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $37,35732 claims |
| PfizerEliquis | $159 | $25,06440 claims |
| BayerKerendia | $268 | $11,33414 claims |
| AbbVieQulipta | $246 | $11,01011 claims |
| MerckJanuvia | $127 | $9,90716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Corinth
- Paul VolanskyCorinth$15K
- Timothy NoyesCorinth$14K
- Sophia ThangCorinth$12K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.